Triptolide Inhibits the Biological Processes of HUVECs and HepG2 Cells via the Serine Palmitoyltransferase Long Chain Base Subunit 2/Sphingosine-1-Phosphate Signaling Pathway

Lulu Jia,1,2,3 Shengnan Zhu,1,2,3 Mingfei Zhu,1,2,3 Lingyue Huang,1,2,3 Siyuan Xu,1,2,3 Yuqin Luo,1,2,3 Juan Xiao,2,3,4,5 Huazhen Su,1 Shaoyuan Huang,1 and Qinyou Tan1,2,3,4,5

1Clinical Pharmacy & Pharmacology Research Institute, Affiliated Hospital of Guilin Medical University, Guilin 541001, China
2Laboratory of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University, Guilin 541001, China
3China-USA Lipids in Health and Disease Research Center, Guilin Medical University, Guilin 541001, China
4Guangxi Key Laboratory of Molecular Medicine in Liver Injury and Repair, Affiliated Hospital of Guilin Medical University, Guilin 541001, China
5Guangxi Health Commission Key Laboratory of Basic Research in Sphingolipid Metabolism Related Diseases, Affiliated Hospital of Guilin Medical University, Guilin 541001, China

Correspondence should be addressed to Qinyou Tan; tqy1013@126.com

Received 18 July 2022; Revised 12 August 2022; Accepted 11 October 2022; Published 18 November 2022

Academic Editor: Zhijie Xu

Copyright © 2022 Lulu Jia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Triptolide (TP) has demonstrated innumerous biological effects and pharmacological potential against different cancer types. Hepatocellular carcinoma has a high incidence in men [1]. The pathogenesis of liver cancer is a very complicated process that includes a series of related processes mediated by various risk factors, such as chronic viral hepatitis, alcohol abuse, nonalcoholic steatohepatitis, and type 2 diabetes [2]. Studies show that angiogenesis plays an important role in the formation of tumors by providing nutrients to tumor cells and that angiogenesis is closely

1. Introduction

Hepatocellular carcinoma is a cancer that has a high incidence in men [1]. The pathogenesis of liver cancer is a very complicated process that includes a series of related processes mediated by various risk factors, such as chronic viral hepatitis, alcohol abuse, nonalcoholic steatohepatitis, and type 2 diabetes [2]. Studies show that angiogenesis plays an important role in the formation of tumors by providing nutrients to tumor cells and that angiogenesis is closely
related to tumor growth and metastasis [3]. In addition, these new vascular tissues can provide blood and nutrients for the continued growth of tumors, and tumor tissues can further promote the regeneration of blood vessels in a variety of ways, thereby forming a vicious cycle. Thus, based on the principles of modern medicine, it is believed that blocking the vascular tissues of tumors can cause the tumors to “starve to death.” Therefore, finding new antivascular and antitumor targets involved in the pathogenesis of liver cancer is a key issue that needs to be addressed. Only by blocking the nutritional supply of tumor tissues and inhibiting their further growth can liver cancer be fundamentally overcome.

In recent years, further study has found that in addition to being the basic component of the cell membrane, sphingolipids also participate in a variety of signal transduction pathways and play important roles in the development of various diseases. The metabolism of sphingolipids is a key pathway in cancer biology, and their metabolites, namely, ceramide, sphingosine, and S1P, together regulate tumor cell death, proliferation, and drug resistance, as well as angiogenesis and inflammation [4]. Ceramide is produced by the hydrolysis of sphingolipids, which can participate in the de novo synthesis of ceramide from the precursor dihydrceramide, which is converted to ceramide by dihydroceramide desaturase to induce tumor cell apoptosis [5]. Ceramide is hydrolyzed by a ceramidase to produce sphingosine, which is phosphorylated by sphingosine kinases 1 and 2 (SK1 and SK2) to produce S1P. S1P also binds to and activates the G protein-coupled receptor family S1P receptor 1-5 (S1PR1-5), which regulates the biological activity of cells [4]. S1P/S1PR signaling pathway plays an important role in maintaining normal tissue physiological functions, such as cell growth and division [6, 7]. In monoculture or monoculture transfection systems, many studies have shown that S1P/S1PRs signaling can promote the process of tumor development, such as promoting the proliferation and migration of tumor cells, promoting angiogenesis, and the formation of tumor microenvironment [7, 8]. However, different S1PRs may have different biological effects. Studies have shown that S1PR2 plays a positive role in apoptosis and autophagy, while S1PR3 has the opposite effect [9]. Studies in many cancer cell lines indicate that S1P induces proliferation [10] and inhibits ceramide-induced apoptosis [6]. Ceramide is a key factor in sphingolipid metabolism, and serine palmitoyltransferase (SPT) is a key enzyme for the de novo synthesis of ceramide. In mammals, SPT is a heterodimer composed of two subunits, namely, serine palmitoyltransferase long chain base subunits 1 and 2 (SPTLC1 and SPTLC2), and serine palmitoyltransferase long chain base subunit 3 (SPTLC3) is the third subunit that was discovered in 2009 [11]. SPT plays an important role in the regulation of growth [12].

TP is one of the main active ingredients extracted from the roots, stems, and leaves of *Triptererygium wilfordii*. TP is a small molecule compound with antitumor, antiangiogenic, anti-inflammatory, and proapoptotic properties [13]. It is found that TP exerts strong inhibitory effect on the biological processes of liver [14, 15], ovarian [16–19], lung [20–22], gastric [23, 24], and breast [25, 26] cancer cells.

Based on the facts mentioned above, this study explored the effects of TP on liver cancer from the three perspectives of antivascular effects, tumor suppression, and the tumor microenvironment and identified a connection between the antiliver cancer effects of TP and sphingolipids. This experiment first studied the effect of TP on HUVECs and its possible mechanism, explored the effect of TP on angiogenesis, and investigated the effect of TP on new angiogenesis targets. Second, this experiment studied the effect of TP on HepG2 cells and further explored a new target for TP to exert its effects against liver cancer. As members of the tumor microenvironment, vascular endothelial cells not only form vascular nutrition tumor tissue but also penetrate the entire tumor tissue. Therefore, do endothelial cells themselves exert a certain effect on tumor cells? Then, this study further explored the interaction between HUVECs and HepG2 cells in a three-dimensional coculture model and its possible mechanism and studied the effect of TP on the coculture system.

### 2. Materials and Methods

#### 2.1. Cell Culture

HUVECs were purchased from the North Branch of the Institute of Biotechnology, and HepG2 cells were purchased from the Chinese Academy of Sciences. The cells were cultured in Dulbeco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% (v/v) penicillin-streptomycin and were maintained at 37°C in a humidified 5% CO₂ incubator.

#### 2.2. Cell Proliferation Assay

Cell viability was determined by CCK-8 assay. In monoculture systems, HUVECs and HepG2 cells were adjusted to a density of 4 × 10⁴ cells/mL and plated into 96-well plates (100 μL/well). HUVECs were treated with TP (0, 12.5, 25, or 50 nM), DMSO (negative control), and endostatin (positive control, 8 mg/L) for 24, 48, and 72 h. HepG2 cells were treated with TP (0, 1, 2, or 4 μM) and DMSO (negative control) for 24 and 48 h. In the monoculture transfection system, HUVECs and HepG2 cells were divided into a SPTLC2 small interfering RNA group (siR-SPTLC2), SPTLC2 plasmid group (SPTLC2), negative control group (siR-NC/SPTLC2-NC), and a blank control group (blank). In addition, HUVECs and HepG2 cells were treated with 25 nM and 2 μM TP for 24 h. In the coculture systems, 2 × 10⁵ HepG2 cells (200 μL/well) were added to the upper chamber of the 24-well coculture system, and 5 × 10⁴ HUVECs (500 μL/well) were added to the lower chamber (coculture). DMEM (500 μL/well) containing 10% FBS was added to the lower chamber in the control group (nonculture). Cells were incubated for 1 to 4 days. In the coculture dosing system, HUVECs were treated with TP (0, 12.5, 25, or 50 nM) and DMSO (negative control) for 24 h, and then, the HUVECs were washed with PBS. These treated HUVECs were cultured with HepG2 cells in the coculture system for 24 h as described.

In monoculture or monoculture transfection systems, the supernatants were removed, and 100 μL of CCK-8 medium (CCK-8 reagent: DMEM = 1 : 10) was added to the wells. In the coculture and coculture dosing systems,
the upper chamber was transferred to a new 24-well plate containing 500 μL of CCK-8 medium (CCK-8 reagent: DMEM = 1 : 10). After 1 to 4 h, the absorbance was measured at 450 nM. We used the OD value to indicate the proliferative ability of the cells.

2.3. Cell Migration and Invasion Assay. The migration ability of HUVECs and HepG2 cells was determined using a 24-well two-compartment transwell assay. Cells in the monoculture, monoculture transfection, coculture, and coculture treatment systems were cultured as described for the proliferation assays. Each group of HUVECs and HepG2 cells (3 × 10^5/200 μL) was resuspended in serum-free DMEM. Two hundred microliters of the cell suspension was added to the upper chamber of the transwell, and 500 μL of complete medium was added to the lower chamber. After 24 h, the upper chamber was removed and washed with phosphate buffered saline (PBS) 3 times. Then, the cells were fixed with 4% tissue cell fixative for 1 h, washed again with PBS 3 times, stained with 0.1% crystal violet for 30 min, and washed again with PBS 3 times. The cells inside the chamber were gently removed with a cotton swab, and the remaining cells were ultimately photographed with a microscope (100×). When imaging was completed, each group of chambers was destained for 5 min in 500 μL of a 10% (v/v) acetic acid solution, and the absorbance was measured at 550 nM.

The cell invasion assay followed a procedure similar to the cell migration assay except that the transwell membrane was pretreated with Matrigel and the HepG2 cells density was adjusted to 3 × 10^5/200 μL.

2.4. Cell Adhesion Assay. The precooled Matrigel (50 μL/well) was placed in a precooled 96-well plate. Then, 2% bovine serum albumin (BSA, 100 μL) was added to each well and incubated for 1 h for blocking. The HUVECs in the monoculture and monoculture transfection systems were cultured as described in the proliferation assay. HUVECs (3 × 10^5/100 μL) were seeded in 96-well plates. After 1 h, the supernatants were removed, and 100 μL of CCK-8 medium (CCK-8 reagent: DMEM = 1 : 10) was added to the wells. After 1 to 4 h, the absorbance was measured at 450 nM.

2.5. Cell Tube Formation Assay. Matrigel was plated in 96-well culture plates and allowed to polymerize at 37°C in 5% CO₂ humidified for 30 min. HUVECs were digested with 0.25% trypsin to prepare a cell suspension, adjusted to a cell density of 8 × 10^3/100 μL, and added to a 96-well plate with Matrigel. Then, 100 μL of cell suspension was added per well, and the cells were imaged after 4-8 h (100×). The quantification of tube formation was carried out by counting the number of branch points.

2.6. PCR Array and RT-PCR Assay. Total RNA was extracted from cells using TRIzol Universal (TIANGEN, Beijing, China) according to the manufacturer’s protocol. Absorbance was measured, and the purity of RNA was assessed using values of 280/260 and 260/230. cDNA was prepared using the PrimeScript RT reagent Kit (TIANGEN, Beijing, China) according to the manufacturer’s instructions. Genetic screening was performed using an RT² Profiler PCR Array kit (QIAGEN, Maryland, USA). The PCR array plate included 48 genes, including 40 target genes and 8 control genes. PCR amplification was performed under the following conditions: 40 cycles at 95°C for 15 s and 60°C for 60 s. GAPDH was used as an internal control. GAPDH forward primer (5'-3'): CAGGGAGCATTGCTGATGAT; GAPDH reverse primer (5'-3'): GAAGGCCGGGGCTCATT; SPTLC2 forward primer (5'-3'): CAGATTGGCTTGGCCAGGAGTTC; SPTLC2 reverse primer (5'-3'): AGTGGGTGTGATCTTCTGCTGATG.

2.7. Western Blotting. After HUVECs and HepG2 cells were treated with drugs or transfected following the above conditions, the protein was extracted for subsequent experiments. The cells were subsequently lysed with RIPA buffer (Solarbio, Beijing, China). Equivalent amounts of protein were separated by 10% SDS-PAGE and transferred to a PVDF membrane. The membranes were blocked in 5% nonfat milk in TBST for 1 h at room temperature and then incubated with primary antibodies at 4°C overnight. The primary antibodies used in this study were purchased from Abcam (Abcam, Cambridge, UK) and included antiserine palmitoyltransferase antibody (ab23696), anti-S1P1 antibody (ab233386), anti-S1PR2 antibody (ab220173), and anti-S1P3 antibody (ab126622). The secondary antibodies were incubated at room temperature. The membrane incubates secondary antibodies at room temperature. After the secondary antibody was incubated, the membrane was observed with ECL plus and X-ray film. Finally, the protein concentration was analyzed using ImageJ.

2.8. Enzyme-Linked Immunosorbent Assay (ELISA). In the monoculture transfection system, HUVECs and HepG2 cells were cultured as described in the proliferation assay. 8 × 10^5 HUVECs (2 mL/well) and 1 × 10^5 HepG2 (2 mL/well) cells were seeded in 6-well plates. After the cells were cultured for 24 h, the supernatants were collected. In the coculture system, 2 × 10^5 HepG2 cells (2 mL/well) were added to the upper chamber of the 6-well coculture chamber, and 1 × 10^6 HUVECs (1 mL/well) were added to the lower chamber. After the cells were cocultured for 1 to 4 days, the supernatants were collected. S1P levels were detected by a sphingosine-1-phosphate ELISA kit (Echelon, Salt Lake, USA) according to the manufacturer’s protocol.

2.9. Statistical Analysis. All data are presented as the mean ± standard deviation (SD). GraphPad Prism 5.0 software was applied for statistical analysis, and the significance between groups was ascertained by one-way ANOVA compared with the least significant difference. When the P value was less than 0.05, the analysis was considered statistically significant.

3. Results

3.1. TP Inhibited HUVECs Proliferation, Migration, Adhesion, and Angiogenesis. First, the effects of TP on HUVECs proliferation were assessed. The results (Figure 1(a)) showed that the TP inhibited the proliferation of
Figure 1: Continued.
HUVECs in a dose- and time-dependent manner, endostatin (positive control) significantly inhibited the proliferation of HUVECs, and DMSO (negative control) had no significant effect on the proliferation of HUVECs. After treating HUVECs with TP (0, 12.5, 25, or 50 nM), DMSO, and endostatin (8 mg/L) for 24 h, the migration (Figure 1(b)), adhesion (Figure 1(c)), and angiogenesis (Figure 1(d)) of HUVECs were measured. The migration capacity of HUVECs was measured in a 24-well transwell chamber. The migrated cells in each chamber were destained (500 μL and 10% acetic acid), and the absorbance was measured at 550 nM to indicate the number of migrated cells. The data showed that TP inhibited HUVECs migration, adhesion, and angiogenesis in a dose-dependent manner, endostatin (positive control) significantly inhibited HUVECs migration, adhesion, and angiogenesis, and DMSO (negative control) had no significant effect on HUVECs migration, adhesion, or angiogenesis.

3.2. TP Downregulated the Expression of SPTLC2 in HUVECs. The results (Figure 2(a)) showed that TP (25 nM) had a regulatory effect on a variety of sphingolipid genes, but among all the genes, SPTLC2 exhibited the largest changes in expression, and SPTLC2 was likely to be a new target of TP. The results are shown as the absolute value of ΔCt. Therefore, we chose SPTLC2 for subsequent studies. HUVECs were treated with TP (25 nM) for 24 h, and the mRNA expression of SPTLC2 in HUVECs was measured by RT-PCR assay. The data (Figure 2(b)) revealed that TP could significantly inhibit the expression of SPTLC2 in HUVECs. HUVECs were treated with TP (0, 12.5, 25, or 50 nM) and DMSO (negative control) for 24 h, and the protein expression of SPTLC2 was detected by western blotting assay. The data (Figure 2(c)) showed that TP could inhibit the expression of SPTLC2 in HUVECs in a dose-dependent manner, and DMSO had no significant effect on SPTLC2.

3.3. SPTLC2 Affected the Proliferation, Migration, Adhesion, Angiogenesis, and S1P Production of HUVECs. The results (Figure 3(a)) showed that the protein expression of SPTLC2 was significantly inhibited in the siR-SPTLC2 (SPTLC2 small interfering RNA) group, the protein expression of SPTLC2 was significantly increased in the SPTLC2 (SPTLC2 plasmid) group, and the protein expression of SPTLC2 was not significantly changed in the siR-NC (SPTLC2 small interfering RNA negative control) and SPTLC2-NC (SPTLC2 plasmid negative control) groups. After HUVECs were transfected with siR-NC, siR-SPTLC2, SPTLC2-NC,
or SPTLC2, their proliferation (Figure 3(b)), migration (Figure 3(c)), adhesion (Figure 3(d)), angiogenesis (Figure 3(e)), and S1P production (Figure 3(f)) were measured. The results showed that siR-SPTLC2 could significantly inhibit the proliferation, migration, adhesion, angiogenesis, and S1P production of HUVECs; SPTLC2 could significantly increase the proliferation, migration, adhesion, angiogenesis, and S1P production of HUVECs; and siR-NC and SPTLC2-NC had no significant effect on the proliferation, migration, adhesion, angiogenesis, and S1P production of HUVECs. On this basis, the proliferation, migration, adhesion, and angiogenesis of HUVECs in each group were further inhibited after treatment with TP (25 nM). Based on these results, SPTLC2 may regulate various biological processes in HUVECs by regulating the production of S1P.

3.4. TP Inhibited the Proliferation, Migration, Invasion, and SPTLC2 mRNA and Protein Expression in HepG2 Cells. Figure 4(a) presents that TP inhibited the proliferation of HepG2 cells in a dose- and time-dependent manner, and DMSO had no significant effect on the proliferation of HepG2 cells. After treating HepG2 cells with TP (0, 1, 2, or 4 μM) and DMSO (negative control) for 24 h, the migration (Figure 4(b)), invasion (Figure 4(c)), and SPTLC2 mRNA (Figure 4(d)) and protein (Figure 4(e)) expression

![Figure 2: TP significantly downregulated the expression of SPTLC2 in HUVECs. (a) HUVECs were treated with TP (25 nM) for 24 h, and the changes in related genes were screened by PCR array assay. The results are shown as the absolute value of ΔCt. (b) HUVECs were treated with TP (25 nM) for 24 h, and the expression of SPTLC2 mRNA was detected by RT-PCR assay. (c) HUVECs were treated with TP (0, 12.5, 25, or 50 nM) and DMSO (negative control) for 24 h, and the protein expression of SPTLC2 in HUVECs was detected by western blotting assay. *P < 0.05, **P < 0.01 versus the control group.](image)
Figure 3: Continued.
Figure 3: Continued.
of HepG2 cells were measured. The migration or invasion capacity of HepG2 cells was assessed in a 24-well transwell chamber, the migrated or invaded cells in each chamber were destained (500 μL and 10% acetic acid), and the absorbance was measured at 550 nM to indicate the number of migrated or invaded cells. The data showed that TP inhibited HepG2 cell migration, invasion, and SPTLC2 mRNA and protein expression in a dose-dependent manner, and DMSO had no significant effect on HepG2 cell migration, invasion, or SPTLC2 mRNA and protein expression.

3.5. SPTLC2 Affected the Proliferation, Migration, Invasion, and S1P Production of HepG2 Cells. The results (Figure 5(a)) showed that the protein expression of SPTLC2 was significantly inhibited in the siR-SPTLC2 (SPTLC2 small interfering RNA) group, the protein expression of SPTLC2 was significantly increased in the SPTLC2 (SPTLC2 plasmid) group, and the protein expression of SPTLC2 was not significantly changed in the siR-NC (SPTLC2 small interfering RNA negative control) and SPTLC2-NC (SPTLC2 plasmid negative control) groups. After HepG2 cells were transfected with siR-NC, siR-SPTLC2, SPTLC2-NC, and SPTLC2, their proliferation (Figure 5(b)), migration (Figure 5(c)), invasion (Figure 5(d)), and S1P production (Figure 5(e)) were measured. The results showed that siR-SPTLC2 could significantly inhibit the proliferation, migration, invasion, and S1P production of HepG2 cells; SPTLC2 could significantly increase the proliferation, migration, invasion, and S1P production of HepG2 cells; and siR-NC and SPTLC2-NC had no significant effect on the proliferation, migration, invasion, and S1P production of HepG2 cells. On this basis, the proliferation, migration, invasion, and S1P production of HepG2 cells were further inhibited after treatment with TP (2 μM). Based on these results, SPTLC2 may regulate various biological processes of HepG2 cells by regulating the production of S1P.

3.6. HUVECs May Induce the Proliferation, Migration, and Invasion of HepG2 Cells via the S1P-S1PRs Pathway. To verify the effect of HUVECs on the proliferation, migration, and invasion of HepG2 cells, HUVECs and HepG2 cells were cocultured to further detect the proliferation, migration, and invasion of HepG2 cells. In the noncocultured or control group, HepG2 cells were added to the upper chamber of the 24-well coculture chamber, and DMEM was added to the lower chamber. In the cocultured group, HepG2 cells were added to the upper chamber of the 24-well coculture chamber, and HUVECs were added to the lower chamber. The HUVECs and HepG2 cells were cocultured for 1 to 4 days. The results (Figure 6(a)) showed that HUVECs promoted the proliferation of HepG2 cells, and their proliferative effects increased as the coculture time increased. HUVECs and HepG2 cells were cocultured for 24 h, and the data showed that HUVECs promoted the migration (Figure 6(b)) and invasion (Figure 6(c)) of HepG2 cells (100×). HUVECs and HepG2 cells were cocultured for 1 to 4 days, and the data showed that the content of S1P (Figure 6(d)) in the coculture system and the protein expression of S1PR1 and S1PR2 (Figure 6(e)) in HepG2 cells increased, while the protein expression of S1PR3 (Figure 6(e)) decreased gradually.

3.7. TP Inhibited the Proliferation, Migration, and Invasion of HepG2 Cells Induced by HUVECs. HUVECs were treated with TP (0, 12.5, 25, or 50 nM) for 24 h, the media was changed to remove the effects of the drug, and the treated HUVECs were cocultured with HepG2 cells in a transwell coculture chamber. HepG2 cells were added to the upper compartment and treated HUVECs were added to the lower compartment. The data showed that when HUVECs were treated with TP, its ability to promote the proliferation (Figure 7(a)), migration (Figure 7(b)), and invasion (Figure 7(c)) of HepG2 cells was significantly inhibited.

4. Discussion

Angiogenesis is known to play an important role in tumor growth and metastasis. The newly formed vascular tissue...
Figure 4: TP inhibited the proliferation, migration, invasion, and SPTLC2 mRNA and protein expression in HepG2 cells. (a) A CCK-8 assay was used to determine HepG2 cell proliferation after treatment with TP (0, 1, 2, or 4 μM) and DMSO (negative control) for 24 and 48 h. After treating HepG2 cells with TP (0, 1, 2, or 4 μM) and DMSO (negative control) for 24 h, the migration (b), invasion (c), and SPTLC2 mRNA (d) and protein (e) expression of HepG2 cells were measured. *P < 0.05, **P < 0.01 versus the control group.
Figure 5: Continued.
can not only lead to the metastasis of tumor cells but also provides a continuous nutritional supply to tumor tissue [27, 28]. Therefore, according to modern medicine principles, the removal of tumor blood vessel tissue can “starve” the tumor. Therefore, in addition to inhibiting the development of tumor tissue, in the treatment of tumors, it is more important to control the formation of new blood vessels. TP is one of the most popular antitumor drugs in recent years. TP inhibits not only tumor angiogenesis but also various tumor biological processes [29–31]. In recent years, studies have found that sphingolipids are not only the basic components of cell membranes but also participate in a variety of signal transduction pathways and play important roles in the development of various diseases, especially tumors [4]. However, the antitumor effect of TP has mainly focused on the tumor suppressor gene p53 [14, 32], microRNAs [33, 34], P-glycoprotein [35], mitogen-activated protein kinases/extracellular signal-regulated kinase (MAPK/ERK) [32], and high-mobility group box 1 (HMGB1) [36], while studies on the sphingolipid signaling pathway are relatively lacking. The signal diagram which indicates the TP effects on sphingolipid signaling pathway is shown in Figure 8.

Figure 5: SPTLC2 can affect the proliferation, migration, invasion, and S1P production of HepG2 cells. After HepG2 cells were transfected with siR-NC (SPTLC2 small interfering RNA negative control), siR-SPTLC2 (SPTLC2 small interfering RNA), SPTLC2-NC (SPTLC2 plasmid negative control), and SPTLC2 (SPTLC2 plasmid), the protein expression of SPTLC2 was detected by western blotting assay (a), and the proliferation (b), migration (c), invasion (d), and S1P production (e) were measured. *P < 0.05, **P < 0.01 versus the blank group.
Figure 6: Continued.
Based on these facts, this research first studied the mechanism underlying the antivascular and antiliver cancer effects of TP. The experimental data showed that TP could down-regulate the expression of SPTLC2 in HUVECs and HepG2 cells, and further transfection experiments showed that the biological behavior of the cells was significantly inhibited after SPTLC2 knockdown, while the biological behavior of the cells was significantly enhanced after SPTLC2 upregulation. In addition, the downregulation of SPTLC2 expression inhibited the production of S1P in two kinds of cells, while upregulation of SPTLC2 expression increased the production of S1P. Based on the above experimental results, SPTLC2 is likely to be a new antivascular and antitumor target of TP, and the regulatory effect of SPTLC2 on cells is likely to be realized by indirectly regulating the production of S1P. SPTLC2 is likely to be a new target for tumor inhibition via sphingolipid-related pathways. Perhaps, the high expression of SPTLC2 is closely related to the development of tumors, and it is very likely to become one of the markers for auxiliary tumor examination.

Angiogenesis is associated with many types of tumors, especially solid tumors, such as liver and breast cancer. As components of the tumor microenvironment, vascular endothelial cells can not only form vascular nutrient tumor tissue but can also penetrate the whole tumor tissue. Therefore, vascular endothelial cells themselves have a certain effect on promoting biological processes of tumor cells. A coculture model is a common method to study interactions between cells. Costa et al. [37] studied the correlation between human hematopoietic stem/progenitor cells and mesenchymal stem/stromal cells using a coculture model. Chen et al. [38] used liver tumors cocultured with stellate cells to study drug resistance and intercellular interactions. Bernhardt et al. [39] studied the interaction between primary human osteoclasts and mature human osteoclasts in a coculture model. Machado et al. [40] investigated the effect of HepG2 cells on endothelial cells through a coculture model. Few studies have investigated the effect of endothelial cells on tumor cells. Thus, this research designed coculture experiments with HUVECs and HepG2 cells. The data showed that the proliferation, migration, and invasion of HepG2 cells cocultured with HUVECs were significantly enhanced compared with HepG2 cells cultured alone. Mechanistic studies have shown that HUVECs may secrete S1P.
1.5
⁎⁎
1.0
⁎
0.5
0.0
OD value

(a)

Control
TP–12.5 nM
TP–25 nM
TP–50 nM

Control
TP–12.5 nM
TP–25 nM
TP–50 nM

(b)

OD value

Control
TP–12.5 nM
TP–25 nM
TP–50 nM

Few Pl. μm

Figure 7: Continued.
and then act on S1PR in HepG2 cells. Our results showed that HUVECs could promote the expression of S1PR2 in HepG2 cells, thereby promoting their proliferation, migration, and invasion. However, Ghosal et al. [9] found that S1PR2 could promote apoptosis and autophagy, which is contrary to our results. This also indicates that the effect of S1PR2 may be opposite in different cells, and its effect may be different or even opposite when the cell environment and other factors are different [41]. Previous reports have shown that S1PR3 plays a positive role in cell proliferation [42]. However, our data showed that HUVECs could inhibit the expression of S1PR3 in HepG2 cells, which may be beneficial for their proliferation, migration, and invasion. Our results suggest that S1PR3 may also have two-sidedness, and more mechanisms need to be further verified by subsequent experiments. This discovery further draws attention to the research field of the effects of vascular endothelial cells on tumor cells and enables us to determine that vascular

**Figure 7:** TP inhibited the proliferation, migration, and invasion of HepG2 cells induced by HUVECs. HUVECs were treated with TP (0, 12.5, 25, or 50 nM) for 24 h, the media was changed to remove the effects of the drugs, and the treated HUVECs were cocultured with HepG2 cells in a transwell coculture chamber. The data showed that when HUVECs were treated with TP, its ability to promote the proliferation (a), migration (b), and invasion (c) of HepG2 cells was significantly inhibited. *P < 0.05, **P < 0.01 versus the control group.

**Figure 8:** The TP effects on sphingolipid signaling pathway.
endothelial cells can also promote the biological processes of tumor cells. These findings provide a theoretical basis for further research on the effects between vascular endothelial cells and tumor cells. However, this conclusion has only been verified in HepG2 cells, and these effects need to be further studied in other tumor cells and animal models. This conclusion may suggest a potential new target for the clinical treatment of tumors. In addition to tumor cells, vascular endothelial cells are also the focus of tumor therapy. Although TP can inhibit a variety of tumor cells through a variety of pathways, its high hepatotoxicity limits its clinical application. Zhao et al. [43] found that TP can induce apoptosis of liver cells by acting on phosphatidylinositol 3-kinases (PI3K), MAPK, tumor necrosis factor α (TNF-α), and p53 signaling pathways and further affect the metabolism of glycerophospholipids, fatty acids, leukotrienes, purines, and pyrimidines, which eventually lead to liver toxicity. Hasnat et al. [44] found that TP can cause mitochondrial dysfunction and mitochondrial autophagy by affecting the generation of reactive oxygen species (ROS), thereby causing toxicity to L02 hepatocytes. Inhibition of the liver toxicity induced by TP is a key issue that urgently needs to be resolved in order to better take advantage of its antitumor effect. However, there are few studies in this field. Tan et al. [45] found that licorice root extract and magnesium isoglycyrrhizinate can inhibit the liver toxicity of TP through the Nrf2 pathway.

In conclusion, the results of this research indicated that TP inhibited the biological processes of HUVECs and HepG2 cells by regulating the SPTLC2-S1P axis and that HUVECs could promote the biological behavior of HepG2 cells. These findings are helpful to further understand the antivascular and antitumor effects of TP via the sphingolipid pathway and to further reveal the role of sphingolipids in the development of tumors.

5. Conclusion

In vitro experiments showed that TP could inhibit the biological behavior of HUVECs and HepG2 cells by downregulating the expression of SPTLC2. SPTLC2 is a promising target for tumor inhibition in the future. HUVECs may promote the biological behavior of HepG2 cells through S1P/S1PR signaling pathway, and TP can inhibit these processes. These results suggest that vascular endothelial cells may affect the prognosis of tumor.

Data Availability

The authors confirm that the data supporting the findings of this study are available within the article.

Disclosure

This paper are written according to our previous preprint “https://www.researchsquare.com/article/rs-629932/v1 [46]."

Conflicts of Interest

The authors declare no conflict of interests.

Authors’ Contributions

LJ and QT conceived and designed the experiments; LJ, QT, SZ, MZ, LH, SX, YL, HS, and SH performed the experiments; LJ, QT, SZ, MZ, and JX analyzed the data; and LJ and QT co-wrote the paper. All the authors read and approved the final manuscript. The authors declare that all data were generated in-house and that no paper mill was used.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (Grants Nos. 81360665, 81767047) and partially supported by the Guangxi Municipal Natural Science Foundation Grants 2015GXNSFAA139114 and 2018GX NSFAA050147. The present study was also supported in part by the Lijiang Scholar Award in Guilin, Hundred Talents Program “the Introduction of Overseas High-Level Talents in Colleges and Universities in Guangxi”, and the High Level of Innovation Team and Outstanding Scholars Program in Colleges and Universities in Guangxi. We thank the scientific research team of the Hepatobiliary and Pancreatic Surgery Laboratory of Affiliated Hospital of Guilin Medical University. Special thanks are due to Dr. Junfei Jin for his guidance on this paper. This manuscript has been published as a preprint, https://www.researchsquare.com/article/rs-629932/v.

References

[1] S. Affo, L. X. Yu, and R. F. Schwabe, “The role of cancer-associated fibroblasts and fibrosis in liver cancer,” Annual Review of Pathology, vol. 12, no. 1, pp. 153–186, 2017.
[2] G. Castelli, E. Pelosi, and U. Testa, “Liver cancer: molecular characterization, clonal evolution and cancer stem cells,” Cancers, vol. 9, no. 9, p. 127, 2017.
[3] G. Dong, X. H. Lin, H. H. Liu et al., “Intermittent hypoxia elevates increased VEGF and pro-angiogenic potential in liver cancer cells,” Oncology Letters, vol. 18, no. 2, pp. 1831–1839, 2019.
[4] C. S. Lewis, C. Voelkel-Johnson, and C. D. Smith, “Targeting sphingosine kinases for the treatment of cancer,” Advances in Cancer Research, vol. 140, pp. 295–325, 2018.
[5] R. Kolesnick and Z. Fuks, “Radiation and ceramide-induced apoptosis,” Oncogene, vol. 22, no. 37, pp. 5897–5906, 2003.
[6] O. A. Sukocheva, H. Furuya, M. L. Ng et al., “Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: a novel therapeutic target,” Pharmacology & Therapeutics, vol. 207, article 107464, 2020.
[7] O. A. Sukocheva, “Expansion of sphingosine kinase and sphingosine-1-phosphate receptor function in normal and cancer cells: from membrane restructuring to mediation of estrogen signaling and stem cell programming,” International Journal of Molecular Sciences, vol. 19, no. 2, p. 420, 2018.
[8] A. H. Janneh and B. Ogetmen, “Targeting sphingolipid metabolism as a therapeutic strategy in cancer treatment,” *Cancers*, vol. 14, no. 9, p. 2183, 2022.

[9] P. Ghosal, O. A. Sukcheeva, T. Wang, G. C. Mayne, D. I. Watson, and D. J. Hussey, “Effects of chemotherapy agents on sphingosine-1-phosphate receptors expression in MCF-7 mammary cancer cells,” *Biomedicine & Pharmacotherapy*, vol. 81, pp. 218–224, 2016.

[10] M. L. Ng, N. S. Yarla, M. Menschikowski, and O. A. Sukcheeva, “Regulatory role of sphingosine kinase and sphingosine-1-phosphate receptor signaling in progenitor/stem cells,” *World Journal of Stem Cells*, vol. 10, no. 9, pp. 119–133, 2018.

[11] T. Hornemann, A. Penno, M. F. Rütti et al., “The SPTLC3 subunit of serine palmitoyltransferase generates short chain sphingoid bases,” *The Journal of Biological Chemistry*, vol. 284, no. 39, pp. 26322–26330, 2009.

[12] E. Ohta, T. Ohira, K. Matsue et al., “Analysis of development of lesions in mice with serine palmitoyltransferase (SPT) deficiency-Sptlc2 conditional knockout mice,” *Experimental Animals*, vol. 58, no. 5, pp. 515–524, 2009.

[13] H. Hu, G. Huang, H. Wang et al., “Inhibition effect of triptolide on human epithelial ovarian cancer via adjusting cellular immunity and angiogenesis,” *Oncology Reports*, vol. 39, no. 3, pp. 1191–1196, 2018.

[14] Y. Y. Sun, L. Xiao, D. Wang et al., “Triptolide inhibits viability and induces apoptosis in liver cancer cells through activation of the tumor suppressor gene p53,” *International Journal of Oncology*, vol. 50, no. 3, pp. 847–852, 2017.

[15] Y. Li and S. Hu, “Triptolide sensitizes liver cancer cell lines to chemotherapy in vitro and in vivo,” *Panninerva Medica*, vol. 56, no. 3, pp. 211–220, 2014.

[16] H. Liu, M. Shen, D. Zhao et al., “The effect of triptolide-loaded exosomes on the proliferation and apoptosis of human ovarian cancer SKOV3 cells,” *BioMed Research International*, vol. 2019, Article ID 2595801, 14 pages, 2019.

[17] G. Huang, H. Hu, Y. Zhang et al., “Triptolide sensitizes cisplatin-resistant human epithelial ovarian cancer by inhibiting the phosphorylation of AKT,” *Journal of Cancer*, vol. 10, no. 13, pp. 3012–3020, 2019.

[18] R. Wang, X. Ma, S. Su, and Y. Liu, “Triptolide antagonized the cisplatin resistance in human ovarian cancer cell line A2780/CP70 via hsa-mir-6751,” *Future Medicinal Chemistry*, vol. 10, no. 16, pp. 1947–1955, 2018.

[19] Y. Wang, T. Liu, and H. Li, “Enhancement of triptolide-loaded micelles on tumorigenicity inhibition of human ovarian cancer,” *Journal of Biomaterials Science. Polymer Edition*, vol. 27, no. 7, pp. 545–556, 2016.

[20] X. Tong, P. Jiang, Y. Li et al., “Combined treatment with triptolide and tyrosine kinase inhibitors synergistically enhances apoptosis in non-small cell lung cancer H1975 cells but not H1299 cells through EGFR/Akt pathway,” *Chemical and Pharmaceutical Bulletin*, vol. 67, no. 8, pp. 864–871, 2019.

[21] Y. Huang, Z. Chen, Y. Wang et al., “Triptolide exerts an anti-tumor effect on non-small cell lung cancer cells by inhibiting activation of the IL-6/STAT3 axis,” *International Journal of Molecular Medicine*, vol. 44, no. 1, pp. 291–300, 2019.

[22] X. Mao, J. Tong, Y. Wang, Z. Zhu, Y. Yin, and Y. Wang, “Triptolide inhibits tumor metastasis by reverting hypermethylation of WIF-1 in lung cancer cells,” *Molecular Medicine Reports*, vol. 18, no. 3, pp. 3041–3049, 2018.

[23] M. Xie, J. Wu, L. Ji et al., “Development of triptolide self-microemulsifying drug delivery system and its anti-tumor effect on gastric cancer xenografts,” *Frontiers in Oncology*, vol. 9, p. 978, 2019.

[24] F. Teng, Z. Y. Xu, H. Lyu et al., “Triptolide reverses apatinib resistance in gastric cancer cell line MKN45 via inhibition of heat shock protein 70,” *Zhonghua Zhong Liu Za Zhi*, vol. 40, no. 2, pp. 92–98, 2018.

[25] W. Zheng, C. Wang, R. Ding, Y. Huang, Y. Li, and Y. Lu, “Triptolide-loaded nanoparticles targeting breast cancer in vivo with reduced toxicity,” *International Journal of Pharmaceutics*, vol. 572, article 118721, 2019.

[26] H. Wu, T. Sun, and R. Bi, “Inhibition of insulin-like growth factor 1 signaling synergistically enhances the tumor suppressive role of triptolide in triple-negative breast cancer cells,” *Oncology Letters*, vol. 18, no. 1, pp. 822–829, 2019.

[27] M. M. Richert, K. S. Vaidya, C. N. Mills et al., “Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone,” *Oncology Reports*, vol. 21, no. 3, pp. 761–767, 2009.

[28] M. Nagahashi, A. Yamada, H. Miyazaki et al., “Intestinal fluid sphingosine-1-phosphate in murine mammary gland cancer and human breast tissue and cancer determined by novel methods,” *Journal of Mammary Gland Biology and Neoplasia*, vol. 21, no. 1-2, pp. 9–17, 2016.

[29] X. Wang, L. Zhang, W. Duan et al., “Anti-inflammatory effects of triptolide by inhibiting the NF-κB signaling pathway in LPS-induced acute lung injury in a murine model,” *Molecular Medicine Reports*, vol. 10, no. 1, pp. 447–452, 2014.

[30] X. Chen, T. Murakami, J. J. Oppenheim, and O. M. Howard, “Triptolide, a constituent of immunosuppressive Chinese herbal medicine, is a potent suppressor of dendritic-cell maturation and trafficking,” *Blood*, vol. 106, no. 7, pp. 2409–2416, 2005.

[31] S. Yang, J. Chen, Z. Guo et al., “Triptolide inhibits the growth and metastasis of solid tumors,” *Molecular Cancer Therapeutics*, vol. 2, no. 1, pp. 65–72, 2003.

[32] M. Yanchun, W. Yi, W. Lu et al., “Triptolide prevents proliferation and migration of esophageal squamous cell cancer via MAPK/ERK signaling pathway,” *European Journal of Pharmacology*, vol. 851, pp. 43–51, 2019.

[33] T. A. Reno, J. Y. Kim, and D. J. Raz, “Triptolide inhibits lung cancer cell migration, invasion, and metastasis,” *The Annals of Thoracic Surgery*, vol. 100, no. 5, pp. 1817–1825, 2015.

[34] Q. Liu, W. Wang, F. Li, D. Yu, C. Xu, and H. Hu, “Triptolide inhibits breast cancer cell metastasis through inducing the expression of miR-146a, a negative regulator of rho GTPase,” *Oncology Research*, vol. 27, no. 9, pp. 1043–1050, 2019.

[35] W. Song, M. Liu, J. Wu, H. Zhai, Y. Chen, and Z. Peng, “Preclinical pharmacokinetics of triptolide: a potential anticancer drug,” *Current Drug Metabolism*, vol. 20, no. 2, pp. 147–154, 2019.

[36] W. Jiang, M. Chen, C. Xiao et al., “Triptolide suppresses growth of breast cancer by targeting HMGB1 in vitro and in vivo,” *Biological & Pharmaceutical Bulletin*, vol. 42, no. 6, pp. 892–899, 2019.

[37] M. H. G. Costa, T. S. Monteiro, S. Cardoso, J. M. S. Cabral, F. C. Ferreira, and C. L. da Silva, “Three-dimensional co-culture of human hematopoietic stem/progenitor cells and mesenchymal stem/stromal cells in a biomimetic hematopoietic niche microenvironment,” in *Stem Cell Niche*, K. Turkens, Ed., vol. 2002 of Methods in Molecular Biology, pp. 101–119, Humana, New York, NY, 2018.
[38] Y. Chen, W. Sun, L. Kang et al., “Microfluidic co-culture of liver tumor spheroids with stellate cells for the investigation of drug resistance and intercellular interactions,” The Analyst, vol. 144, no. 14, pp. 4233–4240, 2019.

[39] A. Bernhardt, V. Österreich, and M. Gelinsky, “Three-dimensional co-culture of primary human osteocytes and mature human osteoclasts in collagen gels,” Tissue Engineering, Part A, vol. 26, no. 11-12, pp. 647–655, 2020.

[40] A. R. T. Machado, A. F. Aissa, D. L. Ribeiro, R. S. Ferreira Jr., S. V. Sampaio, and L. M. G. Antunes, “BjussuLAAO-II induces cytotoxicity and alters DNA methylation of cell-cycle genes in monocultured/co-cultured HepG2 cells,” Journal of Venomous Animals and Toxins including Tropical Diseases, vol. 25, article e147618, 2019.

[41] S. N. Patmanathan, W. Wang, L. F. Yap, D. R. Herr, and I. C. Paterson, “Mechanisms of sphingosine 1-phosphate receptor signalling in cancer,” Cellular Signalling, vol. 34, pp. 66–75, 2017.

[42] O. A. Sukocheva, D. G. Hu, R. Meech, and A. Bishayee, “Divergence of intracellular trafficking of sphingosine kinase 1 and sphingosine-1-phosphate receptor 3 in MCF-7 breast cancer cells and MCF-7-derived stem cell-enriched mammospheres,” International Journal of Molecular Sciences, vol. 22, no. 9, p. 4314, 2021.

[43] J. Zhao, C. Xie, K. Wang et al., “Comprehensive analysis of transcriptomics and metabolomics to understand triptolide-induced liver injury in mice,” Toxicology Letters, vol. 333, pp. 290–302, 2020.

[44] M. Hasnat, Z. Yuan, M. Naveed et al., “Drp1-associated mitochondrial dysfunction and mitochondrial autophagy: a novel mechanism in triptolide-induced hepatotoxicity,” Cell Biology and Toxicology, vol. 35, no. 3, pp. 267–280, 2019.

[45] Q. Y. Tan, Q. Hu, S. N. Zhu et al., “Licorice root extract and magnesium isoglycyrrhizinate protect against triptolide-induced hepatotoxicity via up-regulation of the Nrf2 pathway,” Drug Delivery, vol. 25, no. 1, pp. 1213–1223, 2018.

[46] Q. Y. Tan, S. N. Zhu, M. F. Zhu et al., “Triptolide inhibits the biological processes of HUVEC and HepG2 cells via the serine palmitoyltransferase long chain base subunit 2/sphingosine-1-phosphate signaling pathway,” 2021, https://www.researchsquare.com/article/rs-629932/v1.